Vontobel Holding Ltd. Takes Position in Revvity, Inc. (NYSE:RVTY)

Vontobel Holding Ltd. purchased a new stake in shares of Revvity, Inc. (NYSE:RVTY) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 3,922 shares of the company’s stock, valued at approximately $429,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Gladius Capital Management LP raised its holdings in Revvity by 84.1% in the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after buying an additional 106 shares during the period. CENTRAL TRUST Co purchased a new stake in Revvity in the 4th quarter valued at about $27,000. ORG Partners LLC purchased a new stake in Revvity in the 4th quarter valued at about $32,000. JTC Employer Solutions Trustee Ltd purchased a new stake in Revvity in the 4th quarter valued at about $33,000. Finally, Headinvest LLC purchased a new stake in Revvity in the 3rd quarter valued at about $57,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Stock Up 2.7 %

RVTY stock opened at $103.49 on Wednesday. The company’s 50 day moving average price is $104.74 and its 200 day moving average price is $101.49. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.77 and a current ratio of 2.07. Revvity, Inc. has a fifty-two week low of $79.50 and a fifty-two week high of $135.67. The firm has a market capitalization of $12.78 billion, a price-to-earnings ratio of 18.82, a PEG ratio of 2.63 and a beta of 1.09.

Revvity (NYSE:RVTY) last released its earnings results on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. Revvity had a net margin of 25.20% and a return on equity of 7.41%. The firm had revenue of $695.90 million for the quarter. On average, equities research analysts anticipate that Revvity, Inc. will post 4.65 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, April 18th. Revvity’s dividend payout ratio (DPR) is 5.09%.

Analyst Upgrades and Downgrades

RVTY has been the topic of several research analyst reports. Stifel Nicolaus boosted their price objective on shares of Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a report on Friday, February 2nd. UBS Group lowered shares of Revvity from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $105.00 to $125.00 in a research note on Tuesday, January 16th. KeyCorp boosted their price target on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Raymond James boosted their price target on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Finally, Barclays boosted their price target on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.91.

Insider Activity at Revvity

In related news, insider Prahlad R. Singh sold 21,217 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the transaction, the insider now directly owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.